所有图片(1)
About This Item
经验公式（希尔记法）:
C27H44O2
CAS号:
分子量:
400.64
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24
推荐产品
等級
analytical standard
品質等級
化驗
≥95.0% (HPLC)
應用
clinical testing
格式
neat
儲存溫度
−20°C
SMILES 字串
O=C1CC[C@@]2(C)C(C[C@@H](O)[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@H](C)CCCC(C)C)=C1
InChI
1S/C27H44O2/c1-17(2)7-6-8-18(3)21-9-10-22-25-23(12-14-27(21,22)5)26(4)13-11-20(28)15-19(26)16-24(25)29/h15,17-18,21-25,29H,6-14,16H2,1-5H3/t18-,21-,22+,23+,24-,25+,26+,27-/m1/s1
InChI 密鑰
IOIZWEJGGCZDOL-RQDYSCIWSA-N
相关类别
一般說明
已知7α-羟基-4-胆甾烯-3-酮（C4）是胆固醇7α-羟化酶活性的标志物。在胆汁酸代谢中起重要作用。
應用
C4可作为参比标准品，
- 通过超高效液相色谱-串联质谱法（UHPLC-MS / MS）-电喷雾离子源（ESI）测定人血清中的C4。
- 通过LC-ESI-MS / MS进行多反应监测（MRM）模式检测的大鼠和猴血浆。
- 采用固相萃取（SPE）和HPLC测定外周血血浆。
生化／生理作用
7a-羟基胆甾-3-酮是胆汁酸合成中的代谢产物，来源于 7a-羟基胆固醇，可进一步代谢为 7a,12a,-二羟基胆甾-4-烯-3-酮，用于分析分析血清中 7a-羟基胆甾烯-3-酮 (HCO) 可能作为一种新型、简便、灵敏的方法用于检测不明原因慢性腹泻患者的胆汁酸吸收障碍。
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
A UHPLC-MS/MS method for the quantification of 7?-hydroxy-4-cholesten-3-one to assist in diagnosis of bile acid malabsorption.
Prost JC, et al.
Clinical mass spectrometry, 3, 1-6 (2017)
Comparison of simple extraction procedures in liquid chromatography-mass spectrometry based determination of serum 7?-hydroxy-4-cholesten-3-one, a surrogate marker of bile acid synthesis.
Marek L, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications, 1033, 317-320 (2016)
Monitoring hepatic cholesterol 7?-hydroxylase activity by assay of the stable bile acid intermediate 7?-hydroxy-4-cholesten-3-one in peripheral blood.
Galman C, et al.
Journal of Lipid Research, 44(4), 859-866 (2003)
Lijuan Kang et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1064, 49-55 (2017-09-16)
7α-hydroxy-4-cholesten-3-one (C4) is an oxidative enzymatic product of cholesterol metabolism via cholesterol 7α-hydroxylase, an enzyme also known as cholesterol 7-alpha-monooxygenase or cytochrome P450 7A1 (CYP7A1). C4 is a stable intermediate in the rate limiting pathway of bile acid biosynthesis. Previous
C G Hillebrant et al.
European journal of clinical investigation, 28(4), 324-328 (1998-06-06)
HMG-CoA reductase inhibitors are now the therapy of choice in the treatment of hypercholesterolaemia. The effects of long-term treatment with these substances on plasma lipoproteins, cholesterol metabolism and biliary secretion of lipids have been extensively studied in humans. Much less
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门